Effect of Crataegus oxycantha on gastroesophageal reflux disease (GERD) symptoms

Effect of 10% extract syrup prepared from Crataegus oxycantha versus placebo on gastroesophageal reflux disease (GERD) symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013081314345N1

Enrollment

Registered

2013-12-25

Start date

2013-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease. Gastro-oesophageal reflux disease without oesophagitis

Interventions

Intervention 1: The patients in case group are treated with the drug (10% extract syrup of Crataegus oxycantha)

they should drink 5 ml of the medicine after meal for 4 weeks. Intervention 2: The patients in control group are treated with the placebo and they should take 5 ml of the placebo after meal for 4 week

Treatment - Drugs

The patients in case group are treated with the drug (10% extract syrup of Crataegus oxycantha)

they should drink 5 ml of the medicine after meal for 4 weeks.

The patients in control group are treated with the placebo and they should take 5 ml of the placebo after meal for 4 weeks.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with reflux symptoms (heartburn or regurgitation) occurring at least 2 days a week; patients with uncomplicated reflux; newly diagnosed patients or diagnosed patients who have not used any drugs within the past 2 months. Exclusion criteria: Patients with high urea and creatinine levels; patients with elevated liver enzymes; patients who need to use nonsteroidal anti-inflammatory drugs (NSAIDs) daily; patients who use cardiac glycosides (Digoxin), antiarrhythmic drugs, antiplatelet drugs or Cisapride.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Heartburn, Regurgitasion. Timepoint: At first, end of the second week, end of the forth week. Method of measurement: Clinical; how many days a week a patient suffers from the symptoms.	—

Secondary

Measure	Time frame
Dysphagy, Chest Pain and Cough. Timepoint: At first, end of the second week, end of the forth week. Method of measurement: Clinical; how many days a week a patient has the symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Moini

School of Traditional Medicine, Tehran University of Medical Sciences

farmoini@yahoo.com; f-moini@tums.ac.ir+98 21 2298 8551

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026